Efficacy of Combined Pharmacological and Cognitive- Behavioral Treatments For Anxiety Disorders
By Steven E. Bruce, PhD and Kamila S. White, PhD
Anxiety Disorders
Overview:
Vast Progress but a Long Journey Ahead
By Tracey M. Boudine
Raising the Expectations of Long-Term Treatment Strategies in Anxiety Disorders
By Martin B. Keller, MD
New Developments in Depression and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
Neurobiology and Mechanisms of Antidepressant Treatment Response in Anxiety
By Philip T. Ninan, MD, Sarah A. Feigon, PhD, and Bettina Knight, RN
New Advances in the Management of Anxiety Disorders
By Mark H. Pollack, MD
Advancing the Treatment of Mood and Anxiety Disorders: The First 10 Years’ Experience with Paroxetine
In Vivo Neuroimaging Correlates of the Efficacy of Paroxetine in the Treatment of Mood and Anxiety Disorders
By Clinton Kilts, PhD
Advancing the Treatment of Anxiety Disorders: New Findings and Novel Uses for Atypical Antipsychotics
Studying Non-Human Primates: A Gateway to Understanding Anxiety Disorders
By Ned H. Kalin, MD
Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders
Late-Life Anxiety Disorders
By Carl Salzman, MD
Unmet Needs in the Treatment of Anxiety Disorders
Drug Development for Anxiety Disorders: New Roles for Atypical Antipsychotics
By William H. Carson, MD, Hisashi Kitagawa, PhD, and Charles B. Nemeroff, MD, PhD
EVIDENCE-BASED MEDICINE
A Major Change of Prescribing Pattern in Absence of Adequate Evidence: Benzodiazepines Versus Newer Antidepressants in Anxiety Disorders
By Patricia Berney, Demian Halperin, Rodrigo Tango, Isabelle Daeniker-Dayer, Pierre Schulz
Psychometric Evaluation of a Patient-Rated Troubling Symptom Scale for Generalized Anxiety Disorder Clinical Trials
By Gahan J. Pandina, Dennis A. Revicki, Leah Kleinman, Ibrahim Turkoz, Jasmanda Wu, Ramy Mahmoud, Georges M. Gharabawi